Company intelligence / Profile preview
Stealth BioTherapeutics
George Town, Cayman Islandsstealthbt.com ↗
- Ownership
- Public · MITO
- Employees
- ~38
- Development stage
- Other
01
Overview
Stealth BioTherapeutics develops therapies targeting mitochondrial dysfunction. Its lead candidate elamipretide has completed pivotal studies for Barth syndrome and primary mitochondrial myopathy, with an NDA under FDA review for Barth syndrome as of May 2025. The company also reported a highly protective effect on photoreceptor loss in dry AMD Phase 2 trials. Next-generation candidates like bevemipretide/SBT‐272 are advancing through early clinical stages for rare neurological and ophthalmic diseases.[6]
- Therapeutic areas
- OphthalmologyNeurologyRare DiseasesCardiovascular
- Modalities
- Peptide therapeutics[3][5]Small molecules (pipeline includes SBT series)[3][5]
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Stealth BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stealth BioTherapeutics.